More on AKTX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $10.57 |
|
|||
| Open | $10.63 | ||||
| 52 Wk High | $19.75 | ||||
| 52 Wk Low | $7.63 | ||||
| Day High | $11.07 | ||||
| Day Low | $10.07 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 166,003 | ||||
- Akari Therapeutics to present ADC platform at five September conferences
- Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
- Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
- Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
- Akari Therapeutics shares preclinical data for AKTX-101 in urothelial cancer
- Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
- Akari Therapeutics posts Q2 2026 loss of $4.8M, raises $8.6M
- Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
- Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
- Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
Entities mentioned with AKTX
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Dividend | View Related Stories »
- 13G | View Related Stories »
- Show More...
